2025-07-25 - Analysis Report
Okay, here's the analysis of TG Therapeutics Inc (TGTX), focusing on the provided data:

## TG Therapeutics Inc (TGTX) Stock Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 62.24%
*   **VOO (S&P 500) Cumulative Return:** 98.88%
*   **Absolute Performance Difference:** -36.64%
*   **Relative Performance Difference:** -31.1 (Max: 401.1, Min: -110.5)
*   **Relative Performance Percentile:** 15.5 (Indicates TGTX's performance is in the lower range compared to its historical performance relative to the S&P 500.)

**Analysis:** TGTX has significantly underperformed the S&P 500 over the period analyzed. The relative performance percentile suggests that this underperformance is towards the lower end of its historical range relative to the index.

**Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
|------------|---------|-------|--------|-------|--------|
| 2015-2017  | -6.0%   | 56.5% | -35.0% | -0.1  | 1.3    |
| 2016-2018  | -8.0%   | 58.6% | -26.0% | 0.0   | 0.7    |
| 2017-2019  | 74.0%   | 58.6% | 44.0%  | 0.0   | 1.8    |
| 2018-2020  | 402.0%  | 58.6% | 382.0% | -0.4  | 8.3    |
| 2019-2021  | 125.0%  | 63.5% | 76.0%  | -0.5  | 3.0    |
| 2020-2022  | -76.0%  | 70.4% | -78.0% | -0.6  | 1.9    |
| 2021-2023  | -350.0% | 70.4% | -368.0%| -0.8  | 2.7    |
| 2022-2024  | 71.0%   | 73.1% | 45.0%  | -0.9  | 4.8    |
| 2023-2025  | 69.0%   | 73.1% | 18.0%  | 0.4   | 5.8    |

**Analysis:**

*   **CAGR:** Fluctuates significantly, indicating high volatility in returns. Recent periods (2020-2022, 2021-2023) show substantial losses.
*   **MDD:** Consistently high Maximum Drawdown suggests significant downside risk.
*   **Alpha:**  Alpha is frequently negative, and in recent periods significantly so, meaning TGTX is often underperforming its benchmark on a risk-adjusted basis.
*   **Beta:** Beta is variable. Low or negative Beta values suggest TG Therapeutics Inc. is less volatile than the market as a whole. However the higher Beta values suggest that it is more sensitive to market movements.
*   **Cap(B):** The capitalization varies, reflecting changes in the company's market value.

### 2. Recent Stock Price Movement

*   **Current Price:** $36.53
*   **Previous Close:** $37.60
*   **Change:** -2.85%
*   **5-Day Moving Average:** 37.366
*   **20-Day Moving Average:** 37.2692
*   **60-Day Moving Average:** 36.9214

**Analysis:** The stock price is currently below all three moving averages, suggesting a short-term downtrend. The recent price drop of -2.85% indicates selling pressure.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3274 (Low Risk)
*   **RSI:** 49.17 (Neutral)
*   **PPO:** -0.2198 (Slightly Bearish)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (5 shares - Safe - MRI:0.33) (Cash Ratio: 0% on 2025-07-10)
*   **20-Day Relative Performance Change:** -0.9 (Short-term Decrease)
*   **Expected Return:** -253.8% (Significant Underperformance Expected)

**Analysis:**

*   **MRI:** The MRI suggests a low-risk environment.
*   **RSI:**  The RSI around 50 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** The negative PPO suggests a slight bearish momentum.
*   **Hybrid Signal:** 90% buy
*   **20-Day Relative Performance Change:** Decrease performance compared to its relative past performance.
*   **Expected Return:** A very large negative expected return suggests significant concern about future performance relative to the S&P 500.
*   **Price Change:** The price change (-2.85%) confirms a short-term negative trend and should be considered along with other indicators.

### 4. Recent News & Significant Events

*   **[2025-07-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-23]:** Analyst discussion of recent performance and outlook, influenced by industry trends and global economic factors.
*   **[2025-07-24]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-21]:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news suggests a dynamic environment for TGTX, marked by volatility and significant developments that warrant close attention.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-05-09 | 0.03   | 0.12 B$    |
| 2024-11-07 | 0.03   | 0.08 B$    |
| 2024-08-09 | 0.05   | 0.07 B$    |
| 2024-05-06 | -0.07  | 0.06 B$    |
| 2025-05-09 | -0.07  | 0.06 B$    |

**Analysis:**

*   The most recent EPS is 0.03, showing profitability
*   Revenue is increasing, indicating potential business growth.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-03-31   | $0.12B   | 87.14%        |
| 2024-12-31   | $0.11B   | 85.77%        |
| 2024-09-30   | $0.08B   | 88.86%        |
| 2024-06-30   | $0.07B   | 88.70%        |
| 2024-03-31   | $0.06B   | 91.43%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-03-31   | $0.24B   | 2.13%   |
| 2024-12-31   | $0.22B   | 10.49%  |
| 2024-09-30   | $0.19B   | 2.02%   |
| 2024-06-30   | $0.18B   | 3.87%   |
| 2024-03-31   | $0.16B   | -6.69%  |

**Analysis:**

*   **Revenue:** Increasing trend indicates growth in sales.
*   **Profit Margin:** High profit margins suggest good cost management.
*   **Equity:** Increasing equity shows an improvement in the company's financial position.
*   **ROE:** Highly volatile ROE, showing inconsistency in profitability.

### 7. Overall Summary

*   **Underperformance:** TGTX has significantly underperformed the S&P 500, and its expected return is highly negative.
*   **Volatility:** The stock exhibits high volatility, as indicated by the MDD and fluctuating CAGR and Alpha values.
*   **Short-Term Downtrend:** The stock price is below key moving averages, and recent price action shows selling pressure.
*   **Positive Financial Trends:** Revenue and profit margins show positive trends, suggesting improvements in the company's financial performance.
*   **Recent News:** Recent news indicates significant events influencing the stock and requiring monitoring.
*   **Market Sentiment:** Market Risk Indicator (MRI) is low, but Hybrid signal is to Buy 90%

**Conclusion:**

TGTX presents a mixed picture. While recent financial data shows increasing revenue and high profit margins, the stock's underperformance relative to the S&P 500, negative expected return, and high volatility are significant concerns. The recent news events warrant close monitoring. **Overall, a cautious approach is advisable.  Investors should carefully weigh the potential risks and opportunities before considering an investment in TGTX.**
